IBM Watson Health and Illumina are collaborating to standardize and simplify genomic data interpretation by integrating Watson for Genomics into Illumina’s BaseSpace Sequence Hub and tumor sequencing process. This will give researchers rapid access to information to help interpret the broad array of variant data produced by Illumina’s TruSight Tumor 170, a solid tumor profiling panel designed to detect a comprehensive set of variants across 170 genes. Within minutes, Watson for Genomics will read the genetic alteration files produced by TruSight Tumor 170; comb professional guidelines, medical literature, clinical trials compendia, and other sources for information on each genomic alteration; and produce a report for researchers—a process that typically takes scientists more than 1 week. “To enable precision cancer medicine on a large scale, we need new tools to overcome the data barriers of genomic research,” said Francis deSouza, president and CEO of Illumina. “With a comprehensive assay of Illumina and the power of Watson, we hope to deliver a rapid turnaround of the genomic alteration results.”